New findings from Memorial Sloan Kettering Cancer Center explain a long-standing paradox, revealing two distinct types of regulatory T cells with opposing roles in tumor growth and paving the way for targeted treatments.
New York, NY – For decades, the presence of regulatory T (Treg) cells in most solid tumors has been a harbinger of poor prognosis. These immune cells, acting as the body’s natural "brakes," typically suppress the immune system, thereby blunting its crucial ability to detect and destroy cancerous invaders. This established understanding made colorectal cancer (CRC) a perplexing anomaly: here, a higher concentration of Treg cells often correlated with improved patient survival, a pattern that baffled oncologists and immunologists alike.
Now, a landmark study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has unveiled the long-sought explanation for this paradox. Published in the prestigious scientific journal Immunity, the research fundamentally redefines our understanding of Treg cells in CRC, demonstrating that not all Treg cells are created equal. Instead, the team discovered two distinct subtypes of Treg cells within colorectal tumors, each playing a dramatically different and opposing role in disease progression. This pivotal discovery promises to revolutionize immunotherapy for the vast majority of colorectal cancer patients and potentially extend to other cancers arising in tissues constantly exposed to external stressors, such as the skin, stomach, mouth, and throat.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches in treatment."
The study’s implications are profound, offering a clear roadmap for developing precision immunotherapies that can selectively eliminate the harmful Treg cells while preserving or even enhancing the beneficial ones, thereby unleashing the immune system’s full anti-cancer potential. This represents a significant leap forward, particularly for patients with microsatellite stable (MSS) colorectal cancer, a subgroup that has historically shown limited response to conventional checkpoint inhibitor immunotherapies.
Main Facts: Unraveling the Colorectal Cancer Conundrum
The core breakthrough of the MSK study lies in its resolution of the enduring "Treg paradox" in colorectal cancer. Prior to this research, the prevailing wisdom in oncology dictated that an abundance of regulatory T cells within a tumor microenvironment was generally detrimental. Tregs are known for their immunosuppressive functions, designed to maintain immune tolerance and prevent autoimmune diseases. However, in the context of cancer, this function can be co-opted by tumors to evade immune surveillance and destruction. The inexplicable correlation of higher Treg numbers with better outcomes in CRC had been a persistent source of scientific curiosity and clinical frustration.
The MSK team’s meticulous investigation revealed that the sheer number of Treg cells is not the sole determinant of patient prognosis in CRC. Rather, the composition of the Treg cell population holds the key. They identified two functionally distinct populations:
- Beneficial Treg Cells (IL-10-positive): These cells produce a signaling molecule called interleukin-10 (IL-10). The study found that these IL-10-positive Tregs actively work to slow tumor growth. Their mechanism involves reducing the activity of another immune cell type, Th17 cells, which are known to produce interleukin-17 (IL-17) – a cytokine that paradoxically acts as a growth signal for tumors in this context. Essentially, these beneficial Tregs suppress a pro-tumorigenic pathway. Significantly, these protective cells were more frequently observed in the healthy tissue immediately surrounding the tumor rather than deep within the tumor mass itself.
- Harmful Treg Cells (IL-10-negative): In stark contrast, these Treg cells do not produce IL-10 and exert a detrimental effect on anti-tumor immunity. Their primary function is to suppress powerful immune defenders, most notably CD8+ T cells, which are widely recognized for their direct cancer-killing capabilities. These harmful Tregs were predominantly located within the tumor microenvironment, where they could most effectively shield cancer cells from immune attack.
The pivotal insight is that the beneficial Treg cells are responsible for the previously observed correlation with improved survival, while the harmful ones contribute to disease progression. This dichotomy fundamentally alters the strategic approach to immunotherapy for colorectal cancer, moving beyond broad-spectrum immune modulation towards highly selective targeting.
Chronology: Decades of Dedication Culminate in a Breakthrough
This groundbreaking research is not an isolated discovery but rather the culmination of over two decades of dedicated scientific inquiry by Dr. Alexander Rudensky, a globally recognized authority in the field of regulatory T cell biology. His pioneering work has been instrumental in shaping our foundational understanding of Treg cells, tracing their role from the maintenance of "immune tolerance" to their intricate influence on disease pathogenesis, including cancer.
The Genesis of Treg Understanding
Dr. Rudensky’s journey began with fundamental research establishing the critical role of Treg cells in maintaining immune homeostasis. He and his colleagues were pivotal in demonstrating how these cells prevent autoimmune reactions by distinguishing between harmful pathogens and the body’s own harmless cells, beneficial microbes, and everyday environmental exposures like food antigens. This foundational knowledge elucidated how Treg cells orchestrate a delicate balance, preventing the immune system from launching unwarranted attacks on self-tissues. Over the years, his laboratory meticulously uncovered the mechanisms governing Treg cell development, differentiation, and their diverse functional repertoires across various physiological and pathological contexts. This deep understanding provided the essential framework for investigating their complex roles in cancer.
Addressing the Unmet Need in Colorectal Cancer
Colorectal cancer stands as the second leading cause of cancer-related death when statistics for men and women are combined, according to the American Cancer Society. The MSK study specifically honed in on the most prevalent form of the disease: microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp). This subgroup accounts for a substantial 80% to 85% of all CRC cases. Unfortunately, these tumors are characterized by relatively stable DNA, which makes them inherently less "visible" to the immune system and, consequently, notoriously resistant to conventional checkpoint inhibitor immunotherapies.
Earlier research, also conducted at MSK, had showcased the remarkable efficacy of checkpoint inhibitors against the opposing tumor type – cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). In these cases, the high mutational burden generates numerous neoantigens, making the tumors highly immunogenic and often amenable to successful treatment with immunotherapy alone, frequently sparing patients from the rigors of surgery, chemotherapy, and radiation. However, for the majority of CRC patients with MSS/MMRp tumors, effective immunotherapy options remained elusive, highlighting a significant unmet clinical need.
The present study directly addresses this critical gap. By meticulously dissecting the immune landscape of MSS CRC, the researchers aimed to identify novel therapeutic vulnerabilities. The discovery of the two distinct Treg subtypes represents a significant leap towards developing targeted strategies for this challenging patient population, building directly on the extensive historical understanding of Treg biology and the pressing clinical need for improved outcomes in common CRC.
The research was spearheaded by a collaborative team of first authors: Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, who served as the study’s other senior author. Their combined expertise in immunology, oncology, and computational biology was crucial in deciphering the intricate data and arriving at these groundbreaking conclusions.
Supporting Data: Rigorous Experimentation and Patient Validation
The MSK team employed a sophisticated and multi-pronged approach to uncover and validate their findings, combining advanced mouse models with comprehensive analysis of human patient samples. This robust methodology provided compelling evidence for the existence and opposing functions of the two Treg subtypes.
Elegant Mouse Model Experiments
To precisely explore the immune dynamics within common colorectal cancers, the researchers utilized a highly relevant mouse model developed at MSK. This model was meticulously engineered to closely mirror the genetic alterations, behavioral characteristics, and intricate immune microenvironment observed in human colorectal tumors. This allowed for controlled experimentation and the ability to manipulate specific immune cell populations with unprecedented precision.
Through these detailed experiments, the team made the seminal observation that tumor-associated Treg cells indeed segregated into two primary groups based on their cytokine production profile: those that produce interleukin-10 (IL-10) and those that do not.
The critical phase of the experimentation involved selectively removing each of these distinct Treg groups from the mouse models. This targeted depletion strategy allowed the researchers to directly observe and quantify the specific impact of each Treg subtype on tumor growth and progression.
-
Impact of IL-10-positive Treg cells: When the IL-10-positive Treg cells were selectively eliminated, the tumors in the mouse models grew more quickly. This outcome provided direct evidence that these cells play a protective, tumor-slowing role. Further mechanistic studies revealed that these beneficial Tregs achieve this by actively reducing the activity of Th17 cells. Th17 cells, in turn, are known producers of interleukin-17 (IL-17), a cytokine that was shown to act as a growth signal for colorectal tumors in this context. Thus, IL-10-positive Tregs essentially act as a brake on a pro-tumorigenic pathway. These protective cells were predominantly found in the healthy tissue immediately adjacent to the tumor, suggesting their role might be in maintaining local immune homeostasis or preventing early tumor outgrowth.
-
Impact of IL-10-negative Treg cells: Conversely, the selective removal of IL-10-negative Treg cells led to a dramatic and desirable outcome: tumors became significantly smaller. This provided unequivocal proof that these cells exert a harmful, pro-tumorigenic effect. The mechanism identified was their potent suppression of powerful immune effector cells, particularly CD8+ T cells. CD8+ T cells are the immune system’s frontline soldiers, directly responsible for identifying and destroying cancer cells. By inhibiting these crucial anti-cancer cells, the IL-10-negative Tregs create an immunosuppressive environment that allows tumors to thrive. These harmful Tregs were predominantly localized within the tumor itself, strategically positioned to neutralize immune attacks.
Patient Data Confirmation: Translating Findings to Human Disease
The rigor of the mouse model experiments was further strengthened by robust validation using human colorectal cancer samples. The MSK team analyzed tumor biopsies from patients, confirming the presence of the same two distinct populations of IL-10-positive and IL-10-negative Treg cells within the human tumor microenvironment.
Crucially, the researchers then correlated these cellular findings with patient outcomes. They analyzed data from over 100 colorectal cancer patients, linking the relative abundance of each Treg subtype to survival rates. The results were striking and mirrored the experimental findings: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer survival. Conversely, patients whose tumors were enriched with the harmful IL-10-negative Treg cells experienced poorer outcomes. This direct translational evidence strongly supported the functional distinction observed in the preclinical models and underscored the clinical relevance of the discovery.
Official Responses: A New Era of Selective Immunotherapy
The implications of these findings have been met with significant enthusiasm within the scientific community, particularly from the lead researchers who have dedicated years to unraveling the mysteries of the immune system and cancer. Their statements highlight both the profound nature of the discovery and the exciting therapeutic avenues it opens.
Dr. Alexander Rudensky, a co-senior author and chair of the Immunology Program at MSK, articulated the core message with clarity: "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it." He further emphasized, "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches." This statement encapsulates the paradigm shift – moving away from a blanket suppression of all Tregs, which could inadvertently harm beneficial immune responses, towards a nuanced strategy that targets only the detrimental components.
Dr. Xiao Huang, a first author of the study, underscored the clinical significance of the findings, stating, "This research shows how important these positive cells are. And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." Her remarks directly point to the future direction of therapeutic development: creating precision medicines that can finely tune the immune response, rather than broadly suppressing it. This selectivity is crucial for maximizing anti-tumor effects while minimizing undesirable side effects that often accompany less targeted immunotherapies.
Sneha Mitra, PhD, another first author who led the extensive data analysis, commented on the broader applicability of the findings. "What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," she noted when discussing the similar immune patterns observed in other barrier tissues. This insight suggests that the principles uncovered in colorectal cancer may extend beyond, offering hope for a wider range of cancers that share similar immunological microenvironments.
The consensus among the researchers is clear: the discovery fundamentally alters the understanding of Treg function in colorectal cancer and provides a robust scientific rationale for a new generation of highly selective immunotherapies.
Implications: A Path to Precision Immunotherapy and Beyond
The identification of two functionally opposed Treg subtypes in colorectal cancer holds immense implications for the future of cancer treatment, particularly in the realm of immunotherapy. The study not only solves a long-standing paradox but also provides a tangible therapeutic target that is already being actively pursued.
Targeting CCR8: A New Treatment Strategy Takes Center Stage
Perhaps the most immediate and impactful implication of the study is the identification of a specific molecular target for selectively eliminating harmful Treg cells. The researchers discovered that the detrimental IL-10-negative Treg cells express high levels of a protein called CCR8. Crucially, these CCR8-positive cells are the very ones that actively suppress the anti-tumor immune response and are predominantly found within the tumor microenvironment itself.
This finding is not entirely new territory for Dr. Rudensky’s lab. Earlier collaborative work, notably led by breast cancer surgeon George Plitas, MD, had already established that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and a multitude of other human cancers. That foundational research had previously posited that antibodies designed to specifically target and deplete CCR8-expressing cells could offer a powerful strategy. The premise was that such antibodies could selectively remove the harmful Treg cells, thereby "releasing the brakes" on the immune system and allowing it to mount a more effective attack against tumors, all while leaving the beneficial, non-CCR8-expressing Treg cells intact.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," states Dr. Rudensky, who is also a Howard Hughes Medical Institute Investigator. This underscores the global scientific community’s recognition of CCR8 as a highly promising therapeutic target.
Indeed, this strategy is already advancing rapidly. Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously testing CCR8-targeting antibodies. These trials are evaluating the antibodies both as standalone therapies and in combination with existing immunotherapies, such as checkpoint inhibitors. The new study on colorectal cancer profoundly strengthens the scientific rationale for this approach, providing compelling evidence for its potential efficacy in a major cancer type that has historically been resistant to immunotherapeutic interventions. It solidifies CCR8 as a key target for overcoming immunosuppression in the tumor microenvironment.
Similar Immune Patterns in Other Cancers: Expanding the Therapeutic Horizon
The research team went beyond colorectal cancer, performing an extensive analysis of a large dataset comprising T cells from 16 different cancer types. This broad investigation aimed to determine whether the observed dichotomy between IL-10-positive and IL-10-negative Treg cells, and their distinct roles, might be a more generalizable phenomenon.
Remarkably, they found similar divisions and patterns of Treg cell populations in several other cancer types. These included cancers affecting the skin (e.g., melanoma), and the delicate linings of the mouth, throat, and stomach. This observation is particularly significant because these tissues share a common characteristic: they are "barrier tissues."
As Dr. Mitra highlighted, "What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses." This constant exposure to external factors necessitates a robust and finely tuned immune response, which likely involves complex Treg populations to maintain immune tolerance while also responding to threats. The presence of similar Treg subtypes in these barrier tissue cancers suggests that the therapeutic strategy of removing IL-10-negative, CCR8-positive Treg cells, first validated in colorectal cancer, could potentially be effective against these other malignancies as well. This opens up exciting possibilities for expanding the reach of this precision immunotherapy approach to a wider spectrum of patients.
A Different Immune Balance in Metastatic Disease: Tailoring Treatments to Disease Stage
The study also shed light on the complexities of colorectal cancer progression, specifically examining metastatic disease. When the researchers analyzed colorectal cancer that had spread to the liver, they observed a notably different immune pattern compared to primary tumors.
In these metastatic lesions, the balance between the two Treg subtypes was dramatically shifted. The harmful IL-10-negative Treg cells significantly outnumbered the beneficial IL-10-positive cells. This stark difference suggests a more profoundly immunosuppressive environment in advanced disease. Crucially, unlike primary tumors where selective targeting is paramount, the researchers found that removing all Treg cells in the context of liver metastases led to a reduction in tumor size. This implies that in the metastatic setting, the overall immunosuppressive burden exerted by Tregs might be so overwhelming that a broader depletion strategy could be beneficial, at least in the liver microenvironment.
This critical finding underscores a vital principle in oncology: treatment strategies must account for both the specific tissue involved and the stage of the disease. What works for a primary tumor might not be optimal for metastatic disease, and vice-versa. This nuance highlights the ongoing need for personalized medicine, where therapeutic decisions are tailored not just to the cancer type but also to its specific biological characteristics and its stage of progression.
In conclusion, the MSK study represents a monumental achievement in cancer immunology. By dissecting the intricate roles of regulatory T cells in colorectal cancer, it has not only resolved a long-standing paradox but also provided a clear and actionable path forward for developing highly effective, precision immunotherapies. The focus on selectively targeting harmful Treg cells via CCR8, combined with its potential applicability to other barrier tissue cancers and the nuanced approach to metastatic disease, signals a new era in the fight against cancer. This research brings renewed hope for millions of patients, offering the promise of treatments that are not only more potent but also more precisely tailored to the individual characteristics of their disease.
Authors, Funding, and Disclosures
In addition to the senior and first authors, the research team included Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key institutional resources played crucial roles in the execution of this research, including the Integrated Genomics Operation and the Single Cell Research Initiative at MSK, which provided essential technological and analytical support.
The study received significant financial backing from a consortium of prestigious organizations, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-José Kravis Fellowship in Quantitative Biology.
Dr. Rudensky has disclosed various affiliations, including serving on scientific advisory boards and holding equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Furthermore, Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8, highlighting the translational potential of their ongoing research.
About the Author
